{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:56:50Z","timestamp":1761562610295,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.carrev.2019.05.023","type":"journal-article","created":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T23:26:27Z","timestamp":1559172387000},"page":"361-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Very Late Scaffold Thrombosis after Everolimus-Eluting Bioresorbable Scaffold Implantation in Patients with Unremarkable Interim Surveillance Angiography"],"prefix":"10.1016","volume":"21","author":[{"given":"Petra","family":"Hoppmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshu","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roisin","family":"Colleran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Kufner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Wiebe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Cassese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Joner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl-Ludwig","family":"Laugwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.carrev.2019.05.023_bb0005","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.4244\/EIJ20170912-01","article-title":"Report of an ESC-EAPCI task force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary","volume":"13","author":"Byrne","year":"2018","journal-title":"EuroIntervention."},{"issue":"10018","key":"10.1016\/j.carrev.2019.05.023_bb0010","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(15)00979-4","article-title":"Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials","volume":"387","author":"Cassese","year":"2015","journal-title":"Lancet."},{"issue":"10025","key":"10.1016\/j.carrev.2019.05.023_bb0015","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(15)01039-9","article-title":"1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis","volume":"387","author":"Stone","year":"2016","journal-title":"Lancet."},{"issue":"10","key":"10.1016\/j.carrev.2019.05.023_bb0020","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jcin.2014.07.004","article-title":"Immediate, acute, and subacute thrombosis due to incomplete expansion of bioresorbable scaffolds","volume":"7","author":"Gori","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"issue":"8","key":"10.1016\/j.carrev.2019.05.023_bb0025","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jacc.2015.12.019","article-title":"Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors","volume":"67","author":"Puricel","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"10059","key":"10.1016\/j.carrev.2019.05.023_bb0030","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","article-title":"Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial","volume":"388","author":"Serruys","year":"2016","journal-title":"Lancet."},{"issue":"9","key":"10.1016\/j.carrev.2019.05.023_bb0035","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.4244\/EIJY16M09_01","article-title":"Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial","volume":"12","author":"Onuma","year":"2016","journal-title":"EuroIntervention."},{"issue":"24","key":"10.1016\/j.carrev.2019.05.023_bb0040","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa1614954","article-title":"Bioresorbable scaffolds versus metallic stents in routine PCI","volume":"376","author":"Wykrzykowska","year":"2017","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.carrev.2019.05.023_bb0045","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1093\/eurheartj\/ehx155","article-title":"Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials","volume":"38","author":"Collet","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2019.05.023_bb0050","doi-asserted-by":"crossref","unstructured":"Cassese S, Robert BA, Juni P, Wykrzykowska JJ, Puricel S, Ndrepepa G, et al. Mid-term clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomized trials. EuroIntervention. 2017.","DOI":"10.4244\/EIJ-D-17-00492"},{"issue":"10096","key":"10.1016\/j.carrev.2019.05.023_bb0055","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(17)31470-8","article-title":"2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy","volume":"390","author":"Ali","year":"2017","journal-title":"Lancet."},{"issue":"17","key":"10.1016\/j.carrev.2019.05.023_bb0060","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation."},{"issue":"10","key":"10.1016\/j.carrev.2019.05.023_bb0065","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2008.11.030","article-title":"Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis","volume":"53","author":"Sibbing","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"V","key":"10.1016\/j.carrev.2019.05.023_bb0070","doi-asserted-by":"crossref","first-page":"V159","DOI":"10.4244\/EIJV11SVA39","article-title":"Pathological aspects of bioresorbable stent implantation","volume":"11","author":"Sanchez","year":"2015","journal-title":"EuroIntervention."},{"issue":"3","key":"10.1016\/j.carrev.2019.05.023_bb0075","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1161\/CIRCINTERVENTIONS.113.000990","article-title":"Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model","volume":"7","author":"Otsuka","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.carrev.2019.05.023_bb0080","first-page":"403","article-title":"The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents","volume":"3","author":"Uchida","year":"2010","journal-title":"a critical assessment of \"oculostenotic\" reintervention in patients with intermediate lesions JACC Cardiovascular interventions"},{"issue":"17","key":"10.1016\/j.carrev.2019.05.023_bb0085","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.4244\/EIJY17M02_01","article-title":"Dmax for sizing, PSP-1, PSP-2, PSP-3 or OCT guidance: interventionalist's jargon or indispensable implantation techniques for short- and long-term outcomes of Absorb BRS?","volume":"12","author":"Serruys","year":"2017","journal-title":"EuroIntervention"},{"issue":"14","key":"10.1016\/j.carrev.2019.05.023_bb0090","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.4244\/EIJ-D-16-00471","article-title":"Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging","volume":"12","author":"Sotomi","year":"2017","journal-title":"EuroIntervention."},{"issue":"19","key":"10.1016\/j.carrev.2019.05.023_bb0095","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.jacc.2017.09.014","article-title":"Mechanisms of very late Bioresorbable scaffold thrombosis: the INVEST registry","volume":"70","author":"Yamaji","year":"2017","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838919303227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838919303227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:16:18Z","timestamp":1761560178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838919303227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1553838919303227"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2019.05.023","relation":{},"ISSN":["1553-8389"],"issn-type":[{"type":"print","value":"1553-8389"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Very Late Scaffold Thrombosis after Everolimus-Eluting Bioresorbable Scaffold Implantation in Patients with Unremarkable Interim Surveillance Angiography","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2019.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}